✦ LIBER ✦

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

✍ Scribed by Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John JV McMurray; Eric L Michelson; Bertil Olofsson; Jan Östergren; Salim Yusuf

Book ID: 117284490
Publisher: The Lancet
Year: 2003
Tongue: English
Weight: 129 KB
Volume: 362
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(03)14282-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of Candesartan on Mortality and

Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme

✍ Sricharan Kantipudi; Atul Khasnis 📂 Article 📅 2004 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 117 KB

Trial finds candesartan reduces cardiova

Trial finds candesartan reduces cardiovascular deaths and hospital admissions in people with heart failure, but may not affect all cause mortality: Abstracted from: Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–66

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Prevention of atrial fibrillation in pat

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Anique Ducharme; Karl Swedberg; Marc A. Pfeffer; Alain Cohen-Solal; Christopher 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Effect of candesartan on New York Heart

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme

✍ E. O’Meara; S. Solomon; J. McMurray 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Reduction in all-cause mortality and mor

Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials

✍ James B. Young; Karl Swedberg; Mark E. Dunlap; Marc A. Pfeffer; Jeffrey L. Probs 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

PCV84 Resource Utilization and Costs for

PCV84 Resource Utilization and Costs for Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Programme for the Austrian Setting

✍ F.M. Fruhwald; A.D. Vavrovsky 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB